A Phase 3 interventional study of Venetoclax in Chronic Lymphocytic Leukemia (CLL), sponsored by AbbVie. Completed at 33 sites in 10 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-02-22.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell — 21 open to participants now, 42 under way, 8 of them phase 3. venetoclax · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 14th largest by enrollment, is one of 6 that started in 2016, is one of 15 in phase 3, and was the 19th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →21 of the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Kerry Rogers · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Austria, Brazil and 6 more countries
Ages 18–130
City of Hope Medical Center · Sites in United States
Ages 18+
Zulfa Omer · Sites in United States
Ages 18+
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 44 · Phase 3 15 · Phase 4 1
First in 2011; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 210 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 72 across the 69 interventional studies. Of the 24 that completed or were terminated, 12 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 69 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
51 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AbbVie: 3 open now, 11 under way, 2 of them phase 3. Of 38 finished, 18 (47%) have results posted.
Among the 51 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AbbVie, this one is the 8th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2016, is one of 9 in phase 3, and was the 30th registered.
AbbVie’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2004.
13 of the studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04895436AbbVieStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | 2026-11 |
| NCT03467867Georgetown UniversityA Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | 2026-12 |
| NCT04588922Sellas Life Sciences GroupStudy of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | 2026-12-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among AbbVie’s 51 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
The purpose of this open-label, single-arm study was to evaluate the impact of venetoclax on the quality of life of participants including those with with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL; a type of cancer affecting the blood and the bone marrow) with or without the 17p deletion or TP53 mutation, including participants with an unknown status, as well as R/R CLL participants who had been previously treated with B-cell receptor inhibitor (BCRi) therapy. The starting dose of venetoclax was 20 mg once daily. The dose must have been gradually increased over a period of 5 weeks up to the daily dose of 400 mg. Participants may have continued receiving venetoclax for up to 2 years. After the treatment period, participants may have continued on into a 2-year follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of CLL that meets published 2008 Modified International Workshop on CLL National Cancer Institute - Working Group (IWCLL NCI-WG) Guidelines and:
Exclusion Criteria:
History of active other than CLL within the past 2 years prior to first dose of venetoclax, with the exception of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Venetoclax was administered orally once daily (QD) for a planned duration of up to 2 years or until disease progression; median time on treatment was 127 weeks. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.
Drug: Venetoclax
Venetoclax tablets were to be taken orally once daily with a meal and water in the morning at approximately the same time each day. Tablets were to be swallowed whole and not chewed, crushed, or broken prior to swallowing.
Also known as: ABT-199, VENCLEXTA, VENCLYXTO
Mean Change From Baseline to Week 48 in Global Health Status/Quality of Life (GHS/QoL) Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the global health status/quality of life scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Week 48
Mean Change From Baseline in Global Health Status/Quality of Life (GHS/QoL) Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the global health status/quality of life scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Physical Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a physical functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the physical functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Role Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a role functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the role functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Emotional Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including an emotional functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the emotional functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Cognitive Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a cognitive functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the cognitive functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Social Functioning Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a social functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the social functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Fatigue Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a fatigue scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the fatigue scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Nausea and Vomiting Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a nausea and vomiting scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the nausea and vomiting scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Pain Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a pain scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the pain scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Dyspnea Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a dyspnea scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the dyspnea scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Insomnia Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including an insomnia scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the insomnia scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Appetite Loss Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including an appetite loss scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the appetite loss scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Constipation Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a constipation scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the constipation scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Diarrhea Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a diarrhea scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the diarrhea scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Financial Difficulties Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a financial difficulties scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the financial difficulties scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Fatigue Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)
EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the fatigue scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Treatment Side Effects Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)
EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the treatment side effects scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Disease Effects Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)
EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the disease effects scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Infection Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)
EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the infection scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Social Problems Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)
EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the social problems scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in Future Health Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16)
EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the future health scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale Score
The EQ-5D 5L measures quality of life in five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which are rated on five levels of severity (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, 5: extreme problems), and a separate visual analog scale (VAS). Participants rated their health on a vertical visual analogue scale, where the endpoints were labelled 100, "The best health you can imagine" and 0, "The worst health you can imagine". Positive values indicate improvement from baseline.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Mean Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) Health Index Score
The EQ-5D 5L measures quality of life in five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which are rated on five levels of severity (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, 5: extreme problems), and a separate visual analog scale (VAS). The scores for the 5 dimensions are used to compute a single utility index score ranging from zero (0.0) to 1 (1.0) representing the general health status of the individual, with '0' defined as a health state equivalent to being dead and '1' is full health. The higher the score the better the health status. Positive values indicate improvement from baseline.
Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, Final visit (at study drug discontinuation and/or upon discontinuation from the study, up to Week 108)
Complete Remission Rate (Complete Remission [CR] + Complete Remission With Incomplete Marrow Recovery [CRi])
Complete remission rate (CR + CRi) is defined as the percentage of participants achieving a CR or CRi as their best response (per the investigator assessment) based on 2008 Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) Guidelines criteria.
Time frame: From the first dose of study drug until the last participant completed the Week 48 assessments; median time on follow-up was 184 weeks
Overall Response Rate (ORR)
ORR is defined as the percentage of participants who achieved complete remission (CR), complete remission with incomplete marrow recovery (CRi), nodular partial remission (nPR), or confirmed partial remission (PR) based on the 2008 Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) Guidelines criteria as assessed by investigator using the best response at any time during the study.
Time frame: From the first dose of study drug until the last participant completed the Week 48 assessments; median time on follow-up was 184 weeks
Duration of Overall Response (DOR)
DoR is defined as the number of days from the date of first response (complete remission (CR), complete remission with incomplete marrow recovery (CRi), nodular partial remission (nPR), or confirmed partial remission (PR) based on the 2008 Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) Guidelines criteria to the earliest date of progressive disease (PD) or death. DOR was analyzed by Kaplan-Meier (K-M) methodology.
Time frame: From the first dose of study drug until the last participant completed the Week 48 assessments; median time on follow-up was 184 weeks
Time to Progression (TTP)
TTP is defined as the number of days from the date of first dose of venetoclax to the date of earliest disease progression (PD). TTP was analyzed by Kaplan-Meier (K-M) methodology.
Time frame: From the first dose of study drug until the last participant completed the Week 48 assessments; median time on follow-up was 184 weeks
Progression-Free Survival (PFS)
PFS is defined as the number of days from the date of first dose of venetoclax to the date of earliest disease progression (PD) or death. PFS was analyzed by Kaplan-Meier methodology.
Time frame: From the first dose of study drug until the last participant completed the Week 48 assessments; median time on follow-up was 184 weeks
Overall Survival (OS)
OS is defined as the number of days from the date of first dose of venetoclax to the date of death. For participants who did not die, their data was censored at the date of last study visit or the last known date to be alive, whichever was later. OS was estimated using Kaplan-Meier methodology.
Time frame: From the first dose of study drug until the last participant completed the Week 48 assessments; median time on follow-up was 184 weeks
| Milestone | Venetoclax |
|---|---|
| Started | 210 |
| Completed | 0 |
| Not completed | 210 |
| Withdrew: Death | 63 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Study terminated by sponsor | 4 |
| Withdrew: Completed survival follow-up period | 65 |
| Withdrew: Covid-19 infection | 1 |
| Withdrew: Other, not specified | 66 |
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the global health status/quality of life scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Mean Change From Baseline to Week 48 in Global Health Status/Quality of Life (GHS/QoL) Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) | 9.3 ± 20.11 |
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the global health status/quality of life scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | 3.9 ± 17.65 |
| Week 8 | 6.0 ± 20.67 |
| Week 12 | 7.6 ± 20.13 |
| Week 24 | 9.2 ± 20.29 |
| Week 36 | 9.4 ± 19.45 |
| Week 48 | 9.3 ± 20.11 |
| Week 60 | 10.3 ± 21.83 |
| Week 72 | 10.2 ± 23.87 |
| Week 84 | 11.2 ± 20.96 |
| Week 96 | 8.9 ± 20.92 |
| Week 108 | 9.2 ± 19.97 |
| Final visit | 4.8 ± 23.58 |
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a physical functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the physical functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | 1.2 ± 12.86 |
| Week 8 | 3.0 ± 16.16 |
| Week 12 | 4.6 ± 15.89 |
| Week 24 | 5.2 ± 16.90 |
| Week 36 | 5.6 ± 15.59 |
| Week 48 | 6.1 ± 16.30 |
| Week 60 | 6.0 ± 17.73 |
| Week 72 | 5.7 ± 18.47 |
| Week 84 | 4.8 ± 15.04 |
| Week 96 | 4.0 ± 17.18 |
| Week 108 | 5.7 ± 16.43 |
| Final visit | 1.8 ± 20.52 |
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a role functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the role functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | 2.6 ± 22.75 |
| Week 8 | 4.0 ± 28.31 |
| Week 12 | 7.1 ± 28.60 |
| Week 24 | 9.2 ± 26.85 |
| Week 36 | 9.8 ± 26.70 |
| Week 48 | 10.4 ± 26.10 |
| Week 60 | 8.4 ± 27.63 |
| Week 72 | 11.6 ± 31.01 |
| Week 84 | 9.9 ± 27.38 |
| Week 96 | 8.3 ± 31.23 |
| Week 108 | 11.5 ± 28.03 |
| Final visit | 3.3 ± 33.29 |
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including an emotional functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the emotional functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | 4.9 ± 16.30 |
| Week 8 | 4.7 ± 16.96 |
| Week 12 | 5.7 ± 17.11 |
| Week 24 | 3.6 ± 17.62 |
| Week 36 | 4.3 ± 17.08 |
| Week 48 | 5.7 ± 17.64 |
| Week 60 | 5.2 ± 18.79 |
| Week 72 | 5.1 ± 18.54 |
| Week 84 | 4.0 ± 17.95 |
| Week 96 | 4.2 ± 19.95 |
| Week 108 | 6.1 ± 20.18 |
| Final visit | 1.4 ± 21.78 |
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a cognitive functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the cognitive functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | 2.3 ± 15.61 |
| Week 8 | 4.2 ± 18.93 |
| Week 12 | 4.3 ± 18.29 |
| Week 24 | 3.4 ± 18.42 |
| Week 36 | 3.8 ± 18.54 |
| Week 48 | 3.7 ± 17.15 |
| Week 60 | 4.1 ± 20.01 |
| Week 72 | 4.7 ± 17.65 |
| Week 84 | 3.5 ± 17.91 |
| Week 96 | 1.1 ± 19.58 |
| Week 108 | 5.6 ± 18.75 |
| Final visit | 2.3 ± 20.79 |
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a social functioning scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the social functioning scale indicates a better level of functioning, and positive changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | 2.2 ± 19.14 |
| Week 8 | 5.5 ± 22.13 |
| Week 12 | 6.6 ± 22.26 |
| Week 24 | 7.2 ± 24.79 |
| Week 36 | 8.6 ± 21.63 |
| Week 48 | 9.9 ± 22.80 |
| Week 60 | 9.2 ± 25.78 |
| Week 72 | 9.7 ± 27.41 |
| Week 84 | 8.7 ± 23.95 |
| Week 96 | 8.2 ± 26.14 |
| Week 108 | 11.7 ± 24.21 |
| Final visit | 3.4 ± 29.70 |
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a fatigue scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the fatigue scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | -4.6 ± 18.63 |
| Week 8 | -7.7 ± 22.70 |
| Week 12 | -11.2 ± 24.66 |
| Week 24 | -10.9 ± 20.70 |
| Week 36 | -12.5 ± 23.21 |
| Week 48 | -12.9 ± 21.40 |
| Week 60 | -13.0 ± 22.79 |
| Week 72 | -13.8 ± 25.90 |
| Week 84 | -12.9 ± 23.49 |
| Week 96 | -10.7 ± 24.13 |
| Week 108 | -13.8 ± 22.69 |
| Final visit | -7.5 ± 26.16 |
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a nausea and vomiting scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the nausea and vomiting scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | -0.2 ± 18.02 |
| Week 8 | 0.4 ± 17.19 |
| Week 12 | -0.3 ± 18.50 |
| Week 24 | -1.5 ± 17.24 |
| Week 36 | -2.0 ± 16.19 |
| Week 48 | -0.6 ± 19.45 |
| Week 60 | -0.3 ± 15.42 |
| Week 72 | 0.3 ± 17.40 |
| Week 84 | 0.4 ± 18.00 |
| Week 96 | 0.1 ± 17.15 |
| Week 108 | -1.1 ± 16.28 |
| Final visit | -0.8 ± 17.58 |
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a pain scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the pain scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | -4.6 ± 21.05 |
| Week 8 | -2.9 ± 21.31 |
| Week 12 | -3.6 ± 22.56 |
| Week 24 | -4.1 ± 22.08 |
| Week 36 | -4.0 ± 22.43 |
| Week 48 | -4.6 ± 20.29 |
| Week 60 | -5.2 ± 23.46 |
| Week 72 | -4.7 ± 23.30 |
| Week 84 | -4.6 ± 22.10 |
| Week 96 | 1.1 ± 25.35 |
| Week 108 | -3.4 ± 24.33 |
| Final visit | -0.1 ± 26.50 |
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a dyspnea scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the dyspnea scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | -3.7 ± 23.33 |
| Week 8 | -5.5 ± 26.62 |
| Week 12 | -7.7 ± 29.08 |
| Week 24 | -8.5 ± 26.56 |
| Week 36 | -8.3 ± 28.43 |
| Week 48 | -8.5 ± 27.19 |
| Week 60 | -8.5 ± 26.08 |
| Week 72 | -9.2 ± 31.30 |
| Week 84 | -9.3 ± 26.84 |
| Week 96 | -6.4 ± 28.55 |
| Week 108 | -10.9 ± 27.92 |
| Final visit | -5.3 ± 29.60 |
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including an insomnia scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the insomnia scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | -6.5 ± 25.78 |
| Week 8 | -7.9 ± 30.39 |
| Week 12 | -9.1 ± 29.27 |
| Week 24 | -9.0 ± 27.19 |
| Week 36 | -8.3 ± 30.68 |
| Week 48 | -11.6 ± 25.77 |
| Week 60 | -10.2 ± 28.94 |
| Week 72 | -7.8 ± 29.40 |
| Week 84 | -9.5 ± 28.35 |
| Week 96 | -6.6 ± 29.76 |
| Week 108 | -10.7 ± 26.16 |
| Final visit | -5.3 ± 30.52 |
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including an appetite loss scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the appetite loss scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | -3.4 ± 23.63 |
| Week 8 | -6.2 ± 24.85 |
| Week 12 | -6.0 ± 29.56 |
| Week 24 | -8.8 ± 27.36 |
| Week 36 | -8.1 ± 24.06 |
| Week 48 | -7.8 ± 24.14 |
| Week 60 | -5.6 ± 27.16 |
| Week 72 | -5.1 ± 27.59 |
| Week 84 | -6.9 ± 24.16 |
| Week 96 | -6.4 ± 27.07 |
| Week 108 | -9.3 ± 25.81 |
| Final visit | -4.0 ± 30.36 |
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a constipation scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the constipation scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | 1.7 ± 17.87 |
| Week 8 | 2.5 ± 21.38 |
| Week 12 | 1.4 ± 20.58 |
| Week 24 | 1.1 ± 18.61 |
| Week 36 | -0.8 ± 20.36 |
| Week 48 | -0.2 ± 18.35 |
| Week 60 | 1.7 ± 20.52 |
| Week 72 | 0.5 ± 18.97 |
| Week 84 | 1.7 ± 19.45 |
| Week 96 | 0.7 ± 20.55 |
| Week 108 | -0.8 ± 18.98 |
| Final visit | 1.2 ± 19.64 |
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a diarrhea scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the diarrhea scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | -0.7 ± 20.63 |
| Week 8 | 1.8 ± 21.45 |
| Week 12 | 2.3 ± 22.30 |
| Week 24 | 4.7 ± 21.42 |
| Week 36 | 4.6 ± 21.62 |
| Week 48 | 4.0 ± 21.13 |
| Week 60 | 7.4 ± 27.01 |
| Week 72 | 3.0 ± 25.74 |
| Week 84 | 4.3 ± 23.18 |
| Week 96 | 3.7 ± 22.47 |
| Week 108 | 3.8 ± 21.51 |
| Final visit | 4.9 ± 23.30 |
EORTC QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a financial difficulties scale. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the financial difficulties scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | -6.4 ± 20.07 |
| Week 8 | -4.6 ± 21.91 |
| Week 12 | -6.0 ± 24.54 |
| Week 24 | -7.3 ± 25.05 |
| Week 36 | -7.8 ± 23.70 |
| Week 48 | -8.9 ± 26.52 |
| Week 60 | -10.0 ± 25.96 |
| Week 72 | -8.5 ± 27.99 |
| Week 84 | -10.9 ± 23.06 |
| Week 96 | -8.6 ± 25.34 |
| Week 108 | -9.6 ± 24.04 |
| Final visit | -6.5 ± 25.88 |
EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the fatigue scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | -6.3 ± 32.20 |
| Week 8 | -10.2 ± 38.11 |
| Week 12 | -13.9 ± 38.59 |
| Week 24 | -15.3 ± 37.96 |
| Week 36 | -16.3 ± 34.41 |
| Week 48 | -16.1 ± 35.41 |
| Week 60 | -14.5 ± 36.59 |
| Week 72 | -16.4 ± 36.85 |
| Week 84 | -17.4 ± 34.90 |
| Week 96 | -13.0 ± 35.18 |
| Week 108 | -19.8 ± 35.17 |
| Final visit | -10.6 ± 41.71 |
EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the treatment side effects scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | -2.6 ± 17.70 |
| Week 8 | -4.0 ± 17.84 |
| Week 12 | -4.8 ± 17.96 |
| Week 24 | -7.5 ± 18.46 |
| Week 36 | -7.8 ± 18.03 |
| Week 48 | -7.5 ± 19.19 |
| Week 60 | -6.3 ± 19.41 |
| Week 72 | -6.3 ± 18.73 |
| Week 84 | -6.8 ± 16.43 |
| Week 96 | -6.9 ± 18.48 |
| Week 108 | -8.2 ± 19.33 |
| Final visit | -3.6 ± 22.54 |
EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the disease effects scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | -10.7 ± 19.58 |
| Week 8 | -10.0 ± 21.80 |
| Week 12 | -12.4 ± 23.48 |
| Week 24 | -13.7 ± 23.63 |
| Week 36 | -13.9 ± 23.34 |
| Week 48 | -13.4 ± 23.68 |
| Week 60 | -13.1 ± 23.18 |
| Week 72 | -13.8 ± 23.22 |
| Week 84 | -13.6 ± 22.69 |
| Week 96 | -13.2 ± 22.59 |
| Week 108 | -15.6 ± 24.93 |
| Final visit | -10.2 ± 25.97 |
EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the infection scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | -3.5 ± 21.66 |
| Week 8 | -6.0 ± 29.00 |
| Week 12 | -4.6 ± 28.67 |
| Week 24 | -6.1 ± 26.50 |
| Week 36 | -8.9 ± 26.04 |
| Week 48 | -9.0 ± 25.54 |
| Week 60 | -7.9 ± 25.13 |
| Week 72 | -8.5 ± 28.97 |
| Week 84 | -9.9 ± 24.18 |
| Week 96 | -8.5 ± 25.34 |
| Week 108 | -10.3 ± 25.41 |
| Final visit | -5.5 ± 29.97 |
EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the social problems scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | -4.0 ± 37.50 |
| Week 8 | -7.5 ± 39.15 |
| Week 12 | -8.5 ± 41.06 |
| Week 24 | -10.6 ± 41.72 |
| Week 36 | -13.7 ± 38.15 |
| Week 48 | -15.6 ± 40.85 |
| Week 60 | -15.6 ± 37.18 |
| Week 72 | -17.5 ± 42.76 |
| Week 84 | -15.3 ± 42.14 |
| Week 96 | -14.7 ± 41.79 |
| Week 108 | -16.1 ± 43.85 |
| Final visit | -4.0 ± 48.50 |
EORTC QLQ-CLL16 is comprised of 16 questions that address 5 domains of health-related quality of life important in CLL. Participants rate items and a score ranging from 0 to 100 is calculated. A higher score on the future health scale indicates a lower level of functioning, and negative changes from baseline indicate improvement. A change of 5 - 10 points is considered a small change, and a change of 10 - 20 points is considered a moderate change.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | -17.2 ± 37.82 |
| Week 8 | -21.6 ± 42.94 |
| Week 12 | -25.5 ± 41.77 |
| Week 24 | -23.0 ± 38.96 |
| Week 36 | -24.4 ± 43.97 |
| Week 48 | -24.1 ± 41.75 |
| Week 60 | -25.1 ± 46.09 |
| Week 72 | -27.8 ± 40.59 |
| Week 84 | -20.7 ± 39.68 |
| Week 96 | -24.9 ± 44.18 |
| Week 108 | -23.7 ± 46.63 |
| Final visit | -16.7 ± 49.90 |
The EQ-5D 5L measures quality of life in five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which are rated on five levels of severity (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, 5: extreme problems), and a separate visual analog scale (VAS). Participants rated their health on a vertical visual analogue scale, where the endpoints were labelled 100, "The best health you can imagine" and 0, "The worst health you can imagine". Positive values indicate improvement from baseline.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | 3.67 ± 12.683 |
| Week 8 | 6.00 ± 15.982 |
| Week 12 | 7.75 ± 14.498 |
| Week 24 | 7.78 ± 16.158 |
| Week 36 | 9.08 ± 16.342 |
| Week 48 | 10.34 ± 16.808 |
| Week 60 | 10.84 ± 17.180 |
| Week 72 | 11.19 ± 17.890 |
| Week 84 | 10.22 ± 15.431 |
| Week 96 | 9.98 ± 16.310 |
| Week 108 | 10.77 ± 17.500 |
| Final Visit | 6.22 ± 19.262 |
The EQ-5D 5L measures quality of life in five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which are rated on five levels of severity (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, 5: extreme problems), and a separate visual analog scale (VAS). The scores for the 5 dimensions are used to compute a single utility index score ranging from zero (0.0) to 1 (1.0) representing the general health status of the individual, with '0' defined as a health state equivalent to being dead and '1' is full health. The higher the score the better the health status. Positive values indicate improvement from baseline.
| units on a scale | Venetoclax |
|---|---|
| Week 4 | 0.02 ± 0.135 |
| Week 8 | 0.02 ± 0.130 |
| Week 12 | 0.03 ± 0.122 |
| Week 24 | 0.03 ± 0.112 |
| Week 36 | 0.04 ± 0.121 |
| Week 48 | 0.04 ± 0.124 |
| Week 60 | 0.04 ± 0.129 |
| Week 72 | 0.03 ± 0.132 |
| Week 84 | 0.03 ± 0.111 |
| Week 96 | 0.01 ± 0.134 |
| Week 108 | 0.02 ± 0.124 |
| Final Visit | -0.01 ± 0.172 |
Complete remission rate (CR + CRi) is defined as the percentage of participants achieving a CR or CRi as their best response (per the investigator assessment) based on 2008 Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) Guidelines criteria.
| percentage of participants | Venetoclax |
|---|---|
| Complete Remission Rate (Complete Remission [CR] + Complete Remission With Incomplete Marrow Recovery [CRi]) | 18.6 (13.6 to 24.5) |
ORR is defined as the percentage of participants who achieved complete remission (CR), complete remission with incomplete marrow recovery (CRi), nodular partial remission (nPR), or confirmed partial remission (PR) based on the 2008 Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) Guidelines criteria as assessed by investigator using the best response at any time during the study.
| percentage of participants | Venetoclax |
|---|---|
| Overall Response Rate (ORR) | 76.7 (70.4 to 82.2) |
DoR is defined as the number of days from the date of first response (complete remission (CR), complete remission with incomplete marrow recovery (CRi), nodular partial remission (nPR), or confirmed partial remission (PR) based on the 2008 Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) National Cancer Institute-Working Group (NCI-WG) Guidelines criteria to the earliest date of progressive disease (PD) or death. DOR was analyzed by Kaplan-Meier (K-M) methodology.
| months | Venetoclax |
|---|---|
| Duration of Overall Response (DOR) | 36.0 (30.0 to 38.9) |
TTP is defined as the number of days from the date of first dose of venetoclax to the date of earliest disease progression (PD). TTP was analyzed by Kaplan-Meier (K-M) methodology.
| months | Venetoclax |
|---|---|
| Time to Progression (TTP) | 43.0 (33.4 to 47.2) |
PFS is defined as the number of days from the date of first dose of venetoclax to the date of earliest disease progression (PD) or death. PFS was analyzed by Kaplan-Meier methodology.
| months | Venetoclax |
|---|---|
| Progression-Free Survival (PFS) | 35.5 (32.9 to 42.9) |
OS is defined as the number of days from the date of first dose of venetoclax to the date of death. For participants who did not die, their data was censored at the date of last study visit or the last known date to be alive, whichever was later. OS was estimated using Kaplan-Meier methodology.
| months | Venetoclax |
|---|---|
| Overall Survival (OS) | NA (53.1 to NA) |
Collected over All-cause mortality is reported from enrollment to end of study; median time on follow-up was 184 weeks. TEAEs and SAEs were collected from first dose of study drug until 30 days after last dose of study drug; mean duration on study drug was 123 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Venetoclax | 65/210 (31%) | 106/210 (50.5%) | 179/210 (85.2%) |
| Event | Venetoclax |
|---|---|
| PNEUMONIAInfections and infestations | 21/210 |
| PYREXIAGeneral disorders | 10/210 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 7/210 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 6/210 |
| ANAEMIABlood and lymphatic system disorders | 5/210 |
| HYPERPHOSPHATAEMIAMetabolism and nutrition disorders | 5/210 |
| AUTOIMMUNE HAEMOLYTIC ANAEMIABlood and lymphatic system disorders | 4/210 |
| INFLUENZAInfections and infestations | 4/210 |
| DIARRHOEAGastrointestinal disorders | 3/210 |
| COVID-19 PNEUMONIAInfections and infestations | 3/210 |
| Event | Venetoclax |
|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 90/210 |
| DIARRHOEAGastrointestinal disorders | 66/210 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 58/210 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 39/210 |
| NAUSEAGastrointestinal disorders | 35/210 |
| ANAEMIABlood and lymphatic system disorders | 26/210 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 21/210 |
| COUGHRespiratory, thoracic and mediastinal disorders | 21/210 |
| PYREXIAGeneral disorders | 19/210 |
| HYPERTENSIONVascular disorders | 19/210 |
All enrolled participants who received at least one dose of venetoclax
| Age, Continuous(years) | Venetoclax |
|---|---|
| Mean | 63.9 ± 10.37 |
| Sex: Female, Male(Participants) | Venetoclax |
|---|---|
| Female | 69 |
| Male | 141 |
| Race/Ethnicity, Customized(Participants) | Venetoclax |
|---|---|
| White | 182 |
| Black or African American | 1 |
| Asian | 18 |
| American Indian or Alaska Native | 8 |
| Native Hawaiian or other Pacific Islander | 1 |
| Other | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Dec 2016 to primary completion in Dec 2021, 60 months.
Results were first posted in Feb 2023, 1 year 1 month after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 60 months is above that.
Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Venetoclax
Leukemia, Lymphocytic, Chronic, B-Cell →